Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents

Autor: Piotr J. Wysocki, Nuria Lainez, Stéphane Oudard, Aude Flechon, Gustavo Rubio, Revekka Gyftaki, Iciar Garcia Carbonero, Antoine Angelergues, Sylvestre Le Moulec, Joaquim Bellmunt, Alison Birtle, Javier Munarriz, Mustafa Ozguroglu, Aline Guillot, Eleni Efstathiou, Nicolas Delanoy, Begoña Campos Balea, Emilio Esteban, Daniel Castellano, Iria Gonzalez, P. Borrega

Publikováno v: Clinical Genitourinary Cancer
r-FHPC. Repositorio Institucional de Producción Científica de la Fundación del Hospital Provincial de Castellón
instname

Several agents have demonstrated an overall survival (OS) benefit in metastatic castration-resistant prostate cancer (mCRPC); however, optimal sequencing is unknown. Retrospective analysis of data from 574 mCRPC patients showed increasing OS with the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbfc203151b6ee2935b47d4fa2434c9b
https://pubmed.ncbi.nlm.nih.gov/29550200

Pathologic response to neoadjuvant therapy with nabpaclitaxel plus carboplatin followed by anthracycline regimen in triple-negative breast cancer

Autor: Juan David Cardenas, Carmen Esteban, Iciar Garcia Carbonero, Adriana Rosero, Katherin Martinez Barroso, Miguel Borregon Rivilla, Ana Rosa Rubio Salvador, Paul Martin Aguilar Angulo, Maria Garcia Avila, Jose Ignacio Chacon, Juan Ruiz Martin

Publikováno v: Journal of Clinical Oncology. 37:e12117-e12117

e12117 Background: Triple-negative breast cancer (TNBC) remains a poor prognosis subtype of breast cancer (BC). We are lacking of definitive effective combinations in this tumor. So, it is warranted to explore new combinations. Neo-adjuvant setting i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::860db0b18bb925dfff46063b7ffe18c2
https://doi.org/10.1200/jco.2019.37.15_suppl.e12117

Impact of treatment sequence on the outcomes of metastatic castration resistant prostate cancer patients (mCRPC) with germline BRCA2 mutations: A subanalysis of the PROREPAIR-B study

Autor: Elena Castro, Jose Maria M. Piulats Rodriguez, Enrique Gonzalez-Billalabeitia, David Lorente, Pablo Borrega, Rebeca Lozano, Alejo Rodriguez Vida, Aranzazu Gonzalez del Alba, Rafael Morales Barrera, Angela del Pozo, Iciar Garcia Carbonero, Pablo Lapunzina, Javier Puente, M Isabel Sáez, Eva Fernandez Parra, Nuria Romero-Laorden, María José Méndez-Vidal, Ana Medina, David Olmos, Colin C. Pritchard

Publikováno v: Journal of Clinical Oncology. 36:5071-5071

5071Background: Germline mutations in BRCA2 have been identified in 3-5% of mCRPC patients. PROREPAIR-B (Castro et al ESMO 2017) is the first prospective study to report a worse survival from mCRPC...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3b48d06df186b2d54c36dcc120b14a15
https://doi.org/10.1200/jco.2018.36.15_suppl.5071

Bellini Duct Carcinoma: Series of Two Clinical Cases

Autor: Iciar Garcia Carbonero, Mónica Bernabéu Rodriguez, Elia Martinez Moreno, Ana Karina Santos, Isabel Burgueño, J.D. Cardenas, Blanca Trujillo, Chacón López Muñiz J

Publikováno v: Archives in Cancer Research. 3

Bellini Duct Carcinoma is a rare and aggressive type of Renal Cancer which shares histological and clinical features with Transitional cell carcinomas. We present the two single cases recorded in our hospital with a medical literature review. Althoug

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5043a32575e982f10045970c29f4e89e
https://doi.org/10.21767/2254-6081.100039

How do patterns of progression influence treatment selection after chemohormonal therapy in patients with metastatic hormone sensitive prostate cancer?

Autor: Maria L. Villalobos, Guillermo Velasco, Alejandro Riquelme, Iciar Garcia Carbonero, Isabel Gallegos, Enrique Grande, Alvaro Pinto, Javier Puente, Pablo Gajate, Constanza Maximiano Alonso, Laura Rodriguez, Carmen Perezagua, Carlos Aguado De La Rosa, Almudena Martin, Jf. Rodriguez-Moreno, María J. Garrido, Teresa Alonso, María Sereno, Javier Cassinello, David Marrupe

Publikováno v: Journal of Clinical Oncology. 35:e16504-e16504

e16504 Background: In the CHAARTED and STAMPEDE clinical trials, Docetaxel combined with androgen-deprivation therapy (ADT) increased overall survival in mHSPC patients. Despite the increasing use of this strategy in clinical practice, there is a lac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::360bc6a55a51908e65d1d171f395cb49
https://doi.org/10.1200/jco.2017.35.15_suppl.e16504